FILE PHOTO: Signs and age groups are shown for the Pfizer and Moderna vaccines at a vaccination center as California opens up vaccine eligibility to any residents 16 years and older during the outbreak of coronavirus disease (COVID-19) in Chula Vista, California, U.S., April 15, 2021. REUTERS/Mike Blake
NEW YORK (Reuters) - Wealthy governments are looking to COVID-19 shots from Pfizer Inc and Moderna Inc to keep their vaccination programs on track, as safety concerns and production problems sideline vaccines from AstraZeneca Plc and Johnson & Johnson, public health experts and industry analysts say.
Countries in Europe and Asia, as well as South Africa, are limiting or halting use of AstraZeneca's shot over safety concerns. Rollout of J&J's one-shot vaccine was paused in the United States and Europe this week over a handful of cases of very rare but dangerous blood clots in the brain, much like AstraZeneca's safety issue.
Limited time offer:
Just RM5 per month.
